Advances in the Prevention of Vertical Transmission of Human Immunodeficiency Virus

Seminars in Pediatric Infectious Diseases

Volumn 14, Issue 4, 2003, Pages 295-308

  Mofenson, Lynne M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ANEMIA; BLOOD TOXICITY; BREAST FEEDING; BREAST MILK; CARCINOGENICITY; CESAREAN SECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGENITAL MALFORMATION; DELIVERY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; FEBRILE CONVULSION; GENE MUTATION; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LABOR; LOW BIRTH WEIGHT; LYMPHOCYTE COUNT; META ANALYSIS; OUTCOMES RESEARCH; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRENATAL PERIOD; PUERPERIUM; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TECHNIQUE; TREATMENT FAILURE; UNITED STATES; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 0942276971     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.spid.2003.09.003     Document Type: Article

References (80)

1. Connor EM, Sperling RS, Gelber R, et al: Reduction of maternal-infant transmission of human immunodeficiency vuris type 1 with zidovudine treatment. N Engl J Med 331:1173-1180, 1994.
2. Mofenson LM, the Committee on Pediatric AIDS: Technical report: Perinatal human immunodeficiency virus testing and prevention of transmission. Pediatrics 106:E88, 2000. Available from URL: http://www.pediatrics.org/cgi/contents/full/106/6/e88.
3. World Health Organization/UNAIDS: Report on The Global HIV/AIDS Epidemic, 2002. Geneva, Switzerland, UNAIDS, 2002. Available from URL: http://www.unaids.org
4. Shaffer N, Chuachoowong PA, Mock C, et al: Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial. Lancet 353:773-780, 1999
5. Lallemant M, Jourdain G, Le Coeur S, et al: A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 343:982-991, 2000
6. Dorenbaum A, Cunningham CK, Gelber RD, et al: Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA 288:189-198, 2002
7. Wiktor S, Ekpini E, Karon J, et al: Short course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial. Lancet 353:781-785, 1999
8. Dabis F, Msellati P, Meda N, et al: 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breasefed children in Cote d'Ivoire and Burkina Faso: A double-blind, placebo controlled multicentre trial. Lancet 353:786-792, 1999
9. The Petra Study Team: Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): A randomised, double-blind, placebo-controlled trial. Lancet 359:1178-1186, 2002
10. Guay L, Musoke P, Fleming T, et al: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802, 1999
11. Moodley D, Moodley J, Coovadia H The South African African intrapartum nevirapine trial (SAINT)A multicenter, randomized, coutrolled trial of nevirapine compared to a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother to child transmission of human immunodeficiency virus type-1. J Infect Dis 187:725-735, 2003
12. Van de Perre P: Mother to child transmission of HIV-1: The "all mucosal" hypothesis as a predominant mechanism of transmission. AIDS 13:1133-1138, 1999
13. Sperling RS, Shapiro DE, Coombs RW, et al: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 335:1621, 1996
14. Ioannidis JPA, Abrams EJ, Ammann A, et al: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 183:539-545, 2001
15. Chuachoowong R, Shaffer N, Siriwasin W, et al: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Infect Dis 181:99-106, 2000
16. Tuomala RE, O'Driscoll PT, BremerJW, et al: Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 187:375-384, 2003
17. Wade NA, Birkhead GS, Warren BL, et al: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 339:1409-1414, 1998
18. Rouzioux C, Costagliola D, Burgard M, et al: Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. Am J Epidemiol 142:1330-1337, 1995
19. Leroy V, Karon JM, Alioum A, et al: Twenty-four month efficcacy of a maternal short-course zidovudine regimen to prevent mother to child transmission of HIV-1 in West Africa. AIDS 16:631-641, 2002
20. Mandelbrot L, Landrequ-Mascaro A, Rekacewicz C, et al: Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 285:2083-2093, 2001
21. Chaisilwattana P, Chokephaibulkit K, Chalermchockcharoenkit A, et al: Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 335:1405-1413, 2002
22. Mirochnick M, Fenton T, Gagnier P, et al: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 178:368-374, 1998
23. Musoke P, Guay L, Bagenda D, et al: A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-infected Ugandan women and their neonates (HIVNET 006). AIDS 13:479-486, 1999
24. Eshleman SH, Mracna M, Guay L, et al: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-1957, 2001
25. Nolan M, Fowler MG, Mofenson LM: Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr 30:216-229, 2002
26. Lallemant M, Jourdain G, Le Coeur S, et al: Nevirapine (NVP) during labor and in the neonate significantly improves zidovudine (ZDV) prophylaxis for the prevention of perinatal HIV transmission: Results of PHPT-2 first interim analysis. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002 (abstr LBOr22)
27. Dabis F, Leroy V, Bequet L, et al: Effectiveness of a short course of zidovudine and nevirapine to prevent mother to child transmission (PMTCT) of HIV-1: The Ditrame Plus ANRS 1201 Project in Abidjan, Cote d'Ivorie. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002 (abstr ThOrD1428)
28. Cunningham CK, Chaix M-L, Rekaccwicz C, et al: Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trials Group protocol 316. J Infect Dis 186:181-188, 2002
29. Gray G, Urban M, Violari A, et al: Preliminary analysis of a randomized controlled study to assess the role of post-exposure prophylaxis in reducing mother to child transmission of HIV-1. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002 (abstr LBOr13)
30. Taha TE, Kumwenda N, Gibbons A, et al: Neonatal post-exposure prophylaxis with nevirapine and zidovudine reduces mother to child transmission of HIV. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002 (abstr ThOrD1427)
31. Mofenson LM, Lambert JS, Stiehm ER, et al: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 341:385-393, 1999
32. Garcia PM, Kalish LA, Pitt J, et al: Maternal levels of plasma human immunodeficiency virus type 1 RNA and risk of perinatal transmission. N Engl J Med 341:394-402, 1999
33. Cooper ER, Charurat M, Mofenson L, et al: Combination antiretroviral strategies for treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29:484-494, 2002
34. The International Perinatal HIV Group: The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: A meta-analysis of 15 prospective studies. N Engl J Med 340:977-987, 1999
35. The European Mode of Delivery Collaboration: Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomized clinical trial. Lancet 353:1035-1039, 1999
36. Watts DH, Lambert JS, Stiehm ER, et al: Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of ≤500/uL. Am J Obstet Gynecol 183:100-107, 2000
37. Read JS, Tuomala R, Kpamegan E, et al: Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study. J Acquir Immune Defic Syndr 26:236-245, 2001
38. Marcollet A, Goffinet F, Firtion G, et al: Differences in post-partum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 186:784-789, 2002
39. Rodriguez EJ, Spann C, Jamieson D, et al: Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am J Obstet Gynecol 184:1108-1111, 2001
40. Bulterys M, Chao A, Dushimimana A, et al: Fatal complications after cesarean section in HIV-infected women. AIDS 10:923-924, 1996
41. Biggar RJ, Miotti PG, Taha TE, et al: Perinatal intervention trial in Africa: Effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 347:1647-1650, 1996
42. Gallard P, Mwanyumba F, Verhofstede C, et al: Vaginal lavage with chlorhexidine during labor to reduce mother-to-child HIV transmission: Clinical trial in Mombasa, Kenya. AIDS 15:389-396, 2001
43. Mandelbrot L, Msellati P, Meda N, et al: 15 month follow-up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery. Sex Transm Infect 78:267-270, 2002
44. Taha TE, Biggar RJ, Broadhead RL, et al: Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: Clinical trial. BMJ 315:216-220, 1997
45. Coutsoudis A, Pillay K, Spooner E, et al: Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother to child HIV-1 transmission in Durban, South Africa. AIDS 13:1517-1524, 1999
46. Fawzi WW, Msamanga G, Hunter D, et al: Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania. J Acquir Immune Defic Syndr 23:246-254, 2000
47. Kumwenda N, Mioui PG, Taha TE, et al: Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in Malawi. Clin Infect Dis 35:618-624, 2002
48. Dreyfuss ML, Fawzi WW: Micronutrients and vertical transmission of HIV-1. Am J Clin Nutr 75:959-970, 2002
49. Fawzi WW, Msamanga GI, Hunter D, et al: Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortalily. AIDS 16:1935-1944, 2002
50. Centers for Disease Control and Prevention: U. S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Recomm Rep 44:1-15, 1995
51. Cooper ER, Nugent RP, Diaz C, et al: After AIDS Clinical Trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 174:1207-1211, 1996
52. Wortley PM, Lindegren ML, Fleming PL: Successful implementation of perinatal HIV prevention guidelines: A multistate surveillance evaluation. MMWR Recomm Rep 50:17-28, 2002
53. Bulterys M, Nolan ML, Jamieson DJ, et al: Advances in the prevention of mother-to-child Iransmission: Current issues, future challenges. AIDScience 2 (4), 2002 Available from URL: http://AIDScience.com/Articles/aidscience017.htm
54. The Italian Register For Human Immunodeficiency Virus Infection in Children: Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med 156:915-921, 2002
55. European Collaborative Study: HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 15:761-770, 2001
56. Centers for Disease Control and Prevention: U. S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 51:1-40, 2002
57. Bardeguez AD, Shapiro DE, Mofenson LM, et al: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 32:170-181, 2003
58. Centers for Disease Control and Prevention: HIV testing among pregnant women-United States and Canada, 1998-2001. MMWR Recomm Rep 51:1013-1016, 2002
59. Provisional Committee on Pediatric AIDS: Perinatal human immunodeficiency virus testing. Pediatrics 95:303-307, 1995
60. Joint Statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists: Human immunodeficiency virus screening. Pediatrics 104:128, 1999
61. Centers for Disease Control and Prevention: Progress toward elimination of perinatal HIV infection, Michigan, 1993-2000. MMWR Recomm Rep 51:93-97, 2002
62. Centers for Disease Control and Prevention: Successful implementation of perinatal HIV guidelines: A multistate surveillance evaluation. MMWR Reccomm Rep 50:17-28, 2001
63. Mofenson LM, Munderi P: Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 30:200-215, 2002
64. European Collaborative Study: Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HV-infected women. J Acquir Immune Defic Syndr 32:380-387, 2003
65. Culnane M, Fowler MG, Lee SS, et al: Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 281:151-157, 1999
66. Hanson IC, Autonelli TA, Sperling RS, et al: Lack of tumors in infants with perinatal HIV type 1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr 20:463-467, 1999
67. Antiretroviral Pregnancy Registry Steering Committee: Antiretroviral Pregnancy Registry international interim report for 1 January 1989 through 31 January 2002. Wilmington, NC: Registry Coordinating Center, 2002
68. The European Collaborative Study and the Swiss Mother + Child HIV Collaborative Study: Combination antiretroviral therapy and duration of pregnancy. AIDS 14:2913-2920, 2000
69. Tuomala RE, Shapiro DE, Mofenson LM, et al: Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 346:1863-1870, 2002
70. Blanche S, Tardien M, Rustin P, et al: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354:1084-1089, 1999
71. French Perinatal Cohort Study Group: Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 359:58358-4, 2002
72. Perinatal Safety Review Working Group: Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 25:261-268, 2000
73. Amornwichet P, Tecraratkul A, Simonds RJ, et al: Preventing mother to child HIV transmission: The first year of Thailand's national program. JAMA 288:245-248, 2002
74. Nduati R, John G, Mobori-Ngacha D, et al: Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized trial. JAMA 283:1167-1174, 2000
75. Rousseau CM, Nduati RW, Richardson BA, et al: Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 187:741-747, 2003
76. Coutsoudis A, Pillay K, Kuhn L, et al: Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: Prospective cohort study from Durban, South Africa. AIDS 15:379-387, 2001
77. Fowler MG, Newell ML: Breastfeeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr 30:230-239, 2002
78. Richardson BA, John-Stewart GC, Hughes JP, et al: Breast milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis 187:736-740, 2003
79. Taha TE, Miotti P, Liommba G, et al: HIV, maternal death, and child survival in Africa. AIDS 10:111-112, 1996
80. Nolan ML, Greenberg E, Fowler MG: A view of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies. AIDS 16:1991-1999, 2002